Philips (PHG) has been downgraded from a 'BUY' to a 'HOLD' rating by the Wolf Report Investing Group due to ongoing operational and regulatory risks, including exposure to China, challenges in the sleep segment recovery, and minor litigation issues. The price target was lowered to $25.76 per ADR, reflecting reduced upside potential. The analyst now takes a more conservative stance, signaling caution for investors despite previous optimism about the stock's recovery prospects.
Philips (PHG) shares are trading at USD 28.52 on Pluang as of Nov 03, 2026 16:51 WIB, showing a positive 1-day change of 3.37%. The stock's market capitalization stands at $26.49 billion, reflecting its significant presence in the health sector. Investors on Pluang typically hold PHG for about 86 days, indicating moderate-term interest despite recent rating downgrades.
Philips reported strong Q3 2026 results with an 8% increase in comparable order intake and 3% sales growth, driven by its Diagnosis & Treatment, Personal Health, and Connected Care segments. The adjusted EBITA margin rose by 70 basis points to 13.0%,...
Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by kee...
